Online Table 1. Main inclusion and exclusion criteria among included trials
Trial
Inclusion criteria*
 Stable coronary artery disease or any
acute coronary syndrome
 At least one lesion with a stenosis
≥50% in a vessel with a reference
diameter between 2.25 and 4.00 mm
 Stable coronary artery disease or any
acute coronary syndrome
 At least one lesion with a stenosis
≥50% in a vessel with a reference
diameter between 2.25 and 3.50 mm
Exclusion criteria
 Allergy to antiplatelet drugs, heparin,
stainless steel, contrast agents,
sirolimus, or paclitaxel
SIRTAX
 Participation in another study
 Terminal illness
 Allergy to antiplatelet drugs, heparin,
stainless steel, contrast agents,
sirolimus, or biolimus
 Planned surgery within 6 months of
LEADERS
the index procedure requiring dual
antiplatelet therapy interruption
 Participation in another study
 Pregnancy
 Stable coronary artery disease or any  Allergy to antiplatelet drugs, heparin,
acute coronary syndrome
stainless steel, contrast agents,
sirolimus, or paclitaxel
RESOLUTE All
 At least one lesion with a stenosis
Comers
≥50% in a vessel with a reference
 Participation in another study
diameter between 2.25 and 4.00 mm  Terminal illness
 Childbearing potential
 Stable coronary artery disease or any  Allergy to antiplatelet drugs,
acute coronary syndrome
components of drug-eluting stents
 At least one lesion with a stenosis
 Planned surgery within 6 months of
BIOSCIENCE
≥50% in a vessel suitable for stent
the index procedure requiring dual
implantation
antiplatelet therapy interruption
 Pregnant women
 Participation in another study
*For all trials, no restrictions were applied to the number of treated lesions, number of vessels, or lesion
length.
Online Table 2. SYNTAX score in patients with diabetes, single-, and multi-vessel percutaneous
coronary intervention
Diabetes
(n =1,310)
SYNTAX score
≤22
23-32
>32
13.9±8.8
1090 (83.2%)
178 (13.6%)
42 (3.2%)
PCI: Percutaneous coronary intervention.
Single-vessel PCI Multi-vessel PCI
(n =4,725)
(n =1,353)
11.8±8.1
4224 (89.4%)
404 (8.6%)
97 (2.1%)
17.7±9.2
991 (73.2%)
272 (20.1%)
90 (6.7%)
Online Table 3. Cox-regression analysis for the interaction between the type of drug-eluting
stent and the SYNTAX score
HR (95%CI)
p-value
0.76 (0.64-0.89)
<0.001
1.72 (1.46-1.95)
<0.001
New-generation vs. early-generation DES
0.54 (0.44-0.68)
<0.001
SYNTAX score*
1.73 (1.39-2.06)
<0.001
New-generation vs. early-generation DES
0.36 (0.23-0.56)
<0.001
SYNTAX score*
2.08 (1.34-3.02)
<0.001
Cardiac death, myocardial infarction, or
ischemia-driven TLR
New-generation vs. early-generation DES
SYNTAX score*
Ischemia-driven TLR
Definite stent thrombosis
Hazard ratios (HR) with 95% confidence intervals (CI) are derived from Cox-regressions in which the
SYNTAX score was used as covariate and the type of drug-eluting stent (DES) as a factor. *The SYNTAX
score was log transformed before the analyses (ln[SYNTAX score+1]). The interaction between the type of
DES (new- vs. early-generation DES) and the SYNTAX score was not significant for the composite of cardiac
death, myocardial infarction, or ischemia-driven target-lesion revascularization (TLR) (p =0.16), ischemiadriven TLR (p =0.25), and definite stent thrombosis (p =0.11).
Online Table 4. Cox-regression analysis for the interaction between the type of new-generation
drug-eluting stent and the SYNTAX score
Crude Analysis
Multivariable HR
(95%CI)
p-value
Cardiac death, MI or clinically-indicated TLR
Everolimus-eluting stent
Adjusted Analysis
interaction
p-value**
Multivariable HR
(95%CI)
p-value
0.961
1.00 (Ref)
0.853
1.00 (Ref)
Resolute zotarolimus-eluting stent
0.95 (0.75-1.20)
0.680
0.96 (0.75-1.22)
0.726
Biolimus-eluting stent
0.95 (0.72-1.24)
0.702
0.92 (0.70-1.21)
0.546
Orsiro Sirolimus-eluting stent
0.79 (0.60-1.02)
0.074
0.80 (0.61-1.05)
0.113
SYNTAX score*
1.61 (1.40-1.87)
0.000
1.52 (1.31-1.77)
0.000
Clinically-indicated TLR
Everolimus-eluting stent
0.143
1.00 (Ref)
0.167
1.00 (Ref)
Resolute zotarolimus-eluting stent
1.05 (0.75-1.49)
0.770
1.02 (0.72-1.44)
0.929
Biolimus-eluting stent
1.20 (0.83-1.75)
0.332
1.13 (0.77-1.66)
0.534
Orsiro Sirolimus-eluting stent
0.93 (0.63-1.36)
0.706
0.94 (0.63-1.39)
0.755
SYNTAX score*
1.60 (1.29-1.98)
0.000
1.53 (1.23-1.91)
0.000
Definite stent thrombosis
Everolimus-eluting stent
interaction
p-value**
0.579
1.00 (Ref)
0.623
1.00 (Ref)
Resolute zotarolimus-eluting stent
2.41 (1.06-5.51)
0.037
2.62 (1.11-6.14)
0.027
Biolimus-eluting stent
3.98 (1.77-8.97)
0.001
3.95 (1.68-9.27)
0.002
Orsiro Sirolimus-eluting stent
1.13 (0.39-3.31)
0.825
1.03 (0.32-3.35)
0.960
SYNTAX score*
1.51 (0.93-2.45)
0.097
1.40 (0.85-2.32)
0.188
HR: hazard ratio. CI: confidence intervals. MI: myocardial infarction. TLR: target-lesion revascularization.
*SYNTAX score: ln-transformed[SYNTAX score+1] before analyses. ** p-value of the interaction between the type of new-generation drugeluting stent and the SYNTAX score if added to each of the three models separately. Crude Hazard Ratios HR (95% CI) and p-values are from Cox
Regressions with SYNTAX score (ln-transformed+1) as a covariate and type of new-generation drug-eluting stent as a factor. Adjusted Hazard
Ratios HR (95% CI) and p-values are from Multiple Imputation estimated Cox Regressions (20 data-sets using Rubin's rule to combine estimates)
with SYNTAX score (ln-transformed+1) as a covariate and type of new-generation drug-eluting stent as a factor, adjusting for baseline variables
associated with the primary outcome: age, diabetes, renal failure, previous myocardial infarction.
Online Figure 1. Study Overview
SIRTAX
(n=1,012)
LEADERS
(n=1,707)
RESOLUTE All Comers
(n=2,292)
BIOSCIENCE
(n=2,119)
Patients assessed for the initial screening
(n=7,130)
Exclusion criteria that will be applied:
 Previous coronary artery bypass graft surgery
(n =724)
 SYNTAX Score not available (n =325)
Patients included in the analysis
(n=6,081)
NEW-GENERATION DRUG-ELUTING STENTS
(n=4,554)
EARLY-GENERATION DRUG-ELUTING STENTS
(n=1,527)